The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy

Acta Myologica

Volumn 31, Issue MAY, 2012, Pages 16-20

  McAdam, Laura C ^a,b   Mayo, Amanda L ^c   Alman, Benjamin A ^a,c,d   Biggar, W Douglas ^a,b,d  

^a HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Canada; Deflazacort; Duchenne muscular dystrophy

Indexed keywords

ALENDRONIC ACID; CALCIUM; DEFLAZACORT; PAMIDRONIC ACID; VITAMIN D;

BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CANADA; CATARACTOGENESIS; DUCHENNE MUSCULAR DYSTROPHY; FRACTURE; HEART FUNCTION; HUMAN; LONG BONE FRACTURE; LONG TERM CARE; LUMBAR SPINE; MOBILIZATION; MUSCLE STRENGTH; RESPIRATORY FUNCTION; REVIEW; SCOLIOSIS; SIDE EFFECT; SURVIVAL; VERTEBRA FRACTURE;

ADOLESCENT; ADRENAL CORTEX HORMONES; BODY HEIGHT; BONE DENSITY; CANADA; CATARACT; CHILD; FRACTURES, BONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PREGNENEDIONES; SPINAL INJURIES; SPINE; WALKING; WEIGHT GAIN;

EID: 84861702194     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-89.
3. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008:CD003725.
4. Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20. (Pubitemid 40082930)
5. Moxley RT 3rd, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25:1116-29.
6. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995;50:317-33.
7. Gonzalez-Perez O, Luquin S, Garcia-Estrada J, et al. Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity. Adv Ther 2007;24:1052-60. (Pubitemid 350274784)
8. Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001;138:45-50. (Pubitemid 32097140)
9. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004;14:476-82. (Pubitemid 39141702)
10. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-55.
11. Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-6. (Pubitemid 351221232)
12. Silversides CK, Webb GD, Harris VA, et al. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003;91:769-72. (Pubitemid 36287483)
13. Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy - deflazacort trial. Neuromuscul Disord 1991;1:261-6.
14. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-7.
15. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 1995;17(Suppl):39-43. (Pubitemid 26078840)
16. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol 2003;3:7.
17. Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994;17:386-91. (Pubitemid 24096533)
18. Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Joint Surg Am 2004;86-A:519-24. (Pubitemid 38269022)
19. Scharer K, Feneberg R, Klaus G, et al. Experience with deflazacort in children and adolescents after renal transplantation. Pediatr Nephrol 2000;14:457-63. (Pubitemid 30319232)
20. Lippuner K, Casez JP, Horber FF, et al. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998;83:3795-802. (Pubitemid 28513553)
21. Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985;37:592-3. (Pubitemid 16197164)
22. Ferraris JR, Pasqualini T, Legal S, et al. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol 2000;14:682-8. (Pubitemid 30394453)
23. Loftus CM. Diagnosis and management of nontraumatic subarachnoid hemorrhage in elderly patients. Clin Geriatr Med 1991;7:569-82.
24. Pagano G, Bruno A, Cavallo-Perin P, et al. Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone. Arch Intern Med 1989;149:1098-101. (Pubitemid 19131835)
25. Bruno A, Pagano G, Benzi L, et al. Change in glucose metabolism after long-term treatment with deflazacort and betamethasone. Eur J Clin Pharmacol 1992;43:47-50.
26. Bushby K, Griggs R. 145th ENMC International Workshop: planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands. Neuromuscul Disord 2007;17:423-8. (Pubitemid 46679236)
27. McMillan HJ, Campbell C, Mah JK. Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey. Can J Neurol Sci 2010;37:195-205.
28. Mayo AL, McAdam L, Craven BC, et al. Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord 2012 (submitted for publication).
29. Dooley J, Gordon KE, Dodds L, et al. Duchenne muscular dystrophy: a 30-year population-based incidence study. Clin Pediatr (Phila) 2010;49:177-9.
30. Gauld LM, Kappers J, Carlin JB, et al. Height prediction from ulna length. Dev Med Child Neurol 2004;46:475-80. (Pubitemid 38885846)